Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of MK-6194 in adults with nonsegmental vitiligo
MOH_2023-12-17_012917Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PT101 in nonsegmental vitiligo, sponsored by Merck & Co. Started Dec 2023; status: active, not recruiting.
02
Drugs
PT101
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on MOH_2023-12-17_012917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-12-17_012917.